Apadamtase alfa Other names: ADAMTS13

Therapeutic indications

Apadamtase alfa is indicated for:

ADAMTS13 deficiency in patients with cTTP - on-demand enzyme replacement therapy for acute TTP episodes

Population group: only infants (40 days - 1 year old) , children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Apadamtase alfa is an enzyme replacement therapy (ERT) indicated for the treatment of ADAMTS13 deficiency in children and adult patients with congenital thrombotic thrombocytopenic purpura (cTTP).

Apadamtase alfa can be used for all age groups.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

40 IU/kg of body weight on day 1, 20 IU/kg of body weight on day 2, and thereafter 15 IU/kg of body weight once daily until two days after the acute event is resolved

ADAMTS13 deficiency in patients with cTTP - prophylactic enzyme replacement therapy

Population group: only infants (40 days - 1 year old) , children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Apadamtase alfa is an enzyme replacement therapy (ERT) indicated for the treatment of ADAMTS13 deficiency in children and adult patients with congenital thrombotic thrombocytopenic purpura (cTTP).

Apadamtase alfa can be used for all age groups.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

40 IU/kg of body weight once every other week

< Previous: Overview

Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.